Next Article in Journal
Dealing with the Vicissitudes and Abject Consequences of Head and Neck Cancer: A Vital Role for Psycho-Oncology
Previous Article in Journal
The Down-Regulation of Circ_0059707 in Acute Myeloid Leukemia Promotes Cell Growth and Inhibits Apoptosis by Regulating miR-1287-5p
 
 
Review

Immunogenic Cell Death Role in Urothelial Cancer Therapy

1
UroScience, School of Medical Sciences, University of Campinas, UNICAMP, Campinas, Sao Paulo 13083-970, Brazil
2
Division of Urology/Urooncology, Department of Surgery, School of Medicine, Universidad del Valle, Cali 72824, Colombia
3
Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Sao Paulo 13087-571, Brazil
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(9), 6700-6713; https://doi.org/10.3390/curroncol29090526
Received: 22 August 2022 / Revised: 7 September 2022 / Accepted: 16 September 2022 / Published: 18 September 2022
Purpose: Bladder cancer is the 13th most common cause of cancer death with the highest lifetime cost for treatment of all cancers. This scoping review clarifies the available evidence on the role of a novel therapeutic approach called immunogenic cell death (ICD) in urothelial cancer of the bladder. Methods: In accordance with the recommendations of the Joanna Briggs Institute, we searched MEDLINE (Ovid), EMBASE, CENTRAL databases, and supplemented with manual searches through the conferences, Google scholar, and clinicaltrials.gov for published studies up to April 2022. We included literature that studied molecular mechanisms of ICD and the role of certain danger-associated molecular patterns (DAMPs) in generating ICD, safety and efficacy of different ICD inducers, and their contributions in combination with other urothelial cancer treatments. Results: Oncolytic viruses, radiotherapy, certain chemo/chemo radiation therapy combinations, photodynamic therapy, and novel agents were studied as ICD-inducing treatment modalities in the included studies. ICD was observed in vitro (murine or human urothelial carcinoma) in ten studies, eight studies were performed on mouse models (orthotopic or subcutaneous), and five clinical trials assessed patient response to ICD inducing agents. The most common studied DAMPs were Calreticulin, HMGB1, ATP, and Heat Shock Proteins (HSP) 70 and 90, which were either expressed on the cancer cells or released. Conclusion: ICD inducers were able to generate lasting antitumor immune responses with memory formation in animal studies (vaccination effect). In clinical trials these agents generally had low side effects, except for one trial, and could be used alone or in combination with other cancer treatment strategies in urothelial cancer patients. View Full-Text
Keywords: bladder cancer; immunogenic cell death; immunotherapy; immune checkpoint inhibitors; scoping review bladder cancer; immunogenic cell death; immunotherapy; immune checkpoint inhibitors; scoping review
Show Figures

Figure 1

MDPI and ACS Style

Yadollahvandmiandoab, R.; Jalalizadeh, M.; Buosi, K.; Garcia-Perdomo, H.A.; Reis, L.O. Immunogenic Cell Death Role in Urothelial Cancer Therapy. Curr. Oncol. 2022, 29, 6700-6713. https://doi.org/10.3390/curroncol29090526

AMA Style

Yadollahvandmiandoab R, Jalalizadeh M, Buosi K, Garcia-Perdomo HA, Reis LO. Immunogenic Cell Death Role in Urothelial Cancer Therapy. Current Oncology. 2022; 29(9):6700-6713. https://doi.org/10.3390/curroncol29090526

Chicago/Turabian Style

Yadollahvandmiandoab, Reza, Mehrsa Jalalizadeh, Keini Buosi, Herney Andrés Garcia-Perdomo, and Leonardo Oliveira Reis. 2022. "Immunogenic Cell Death Role in Urothelial Cancer Therapy" Current Oncology 29, no. 9: 6700-6713. https://doi.org/10.3390/curroncol29090526

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop